PXD015360 is an
original dataset announced via ProteomeXchange.
Dataset Summary
Title | Comparative glycoproteomic profiling of human body fluid between healthy controls and patients with papillary thyroid carcinoma |
Description | Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer among women worldwide. It is confirmed mainly by fine-needle aspiration biopsy (FNAB), an invasive diagnostic method. The key proteins responsible for thyroid hormone biosynthesis are glycosylated. Changes in site-specific glycosylation are associated with thyroid cancer. Integrated quantitative proteomic and glycoproteomic analyses of body fluids from patients with PTC may identify potential noninvasive biomarkers, improve diagnostic accuracy, and elucidate the basic mechanisms of tumor development. In the present study, we demonstrated a novel integrated method of body fluid proteome and glycoproteome analysis. We showed that it is highly reproducible and fast. It may also quantitatively profile protein glycosylation. Intact N-glycopeptides from the urine and plasma of healthy controls (HC), PTC, and PTC with Hashimoto’s thyroiditis (PHT) were enriched by hydrophilic interaction liquid chromatography. Sialic acid was removed from the N-glycopeptides with trifluoroacetic acid and heat. The desialo-N-glycopeptides were analyzed by HCD-MS/MS using stepped collision energies and several search engines for quantitative profiling. Ninety-two altered proteins and 134 intact N-glycopeptides were isolated from the plasma and urine samples of the three groups (90 samples from 15 subjects). To the best of our knowledge, this study is the first to compare the plasma and urinary proteomes and glycoproteomes of HC, PTC, and PHT. Moreover, we revealed a novel indicator (ratio of fucosylated to non-fucosylated N-glycopeptide or F/NF) through desialo-N-glycopeptide analysis. These differently expressed glycoproteins and F/NF may serve as biomarkers contributing to clinical cancer diagnostics and could be used to improve diagnostic accuracy noninvasively. |
HostingRepository | PRIDE |
AnnounceDate | 2019-12-09 |
AnnouncementXML | Submission_2019-12-09_01:50:03.xml |
DigitalObjectIdentifier | |
ReviewLevel | Peer-reviewed dataset |
DatasetOrigin | Original dataset |
RepositorySupport | Unsupported dataset by repository |
PrimarySubmitter | Yong Zhang |
SpeciesList | scientific name: Homo sapiens (Human); NCBI TaxID: 9606; |
ModificationList | iodoacetamide derivatized residue; deamidated residue |
Instrument | Orbitrap Fusion Lumos |
Dataset History
Revision | Datetime | Status | ChangeLog Entry |
0 | 2019-09-09 02:51:01 | ID requested | |
⏵ 1 | 2019-12-09 01:50:04 | announced | |
2 | 2024-10-22 04:58:29 | announced | 2024-10-22: Updated project metadata. |
Publication List
Zhang Y, Zhao W, Zhao Y, Mao Y, Su T, Zhong Y, Wang S, Zhai R, Cheng J, Fang X, Zhu J, Yang H, Comparative Glycoproteomic Profiling of Human Body Fluid between Healthy Controls and Patients with Papillary Thyroid Carcinoma. J Proteome Res, 19(7):2539-2552(2020) [pubmed] |
Keyword List
submitter keyword: biomarker |
mass spectrometry |
site-specific N-glycopeptide |
thyroid cancer |
Contact List
Yong Zhang |
contact affiliation | Sichuan University, Westchina Hospital |
contact email | nankai1989@foxmail.com |
lab head | |
Yong Zhang |
contact affiliation | Sichuan University |
contact email | nankai1989@foxmail.com |
dataset submitter | |
Full Dataset Link List
Dataset FTP location
NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/12/PXD015360 |
PRIDE project URI |
Repository Record List
[ + ]
[ - ]
- PRIDE
- PXD015360
- Label: PRIDE project
- Name: Comparative glycoproteomic profiling of human body fluid between healthy controls and patients with papillary thyroid carcinoma